Cancer Management and Research最新文献

{"title":"Research Progress on the Relationship Between Radiation Enteritis and Gut Microbiota Dysbiosis.","authors":"Jingru Xu, Yulin Liu, Yilin Xiao, Yuxing Chen, Enqing Meng, Min Jin, Mengjiao Wu, Yan Zong, Hongli Liu","doi":"10.2147/CMAR.S640003","DOIUrl":"10.2147/CMAR.S640003","url":null,"abstract":"<p><p>Radiation enteritis (RE) is the most common complication of pelvic radiotherapy, often manifesting as diarrhea, hematochezia, and tenesmus. In some cases, it progresses to chronic radiation enteritis, leading to intestinal fibrosis and fistula formation, which severely impacts patients'quality of life and prognosis. Current therapeutic strategies for RE include radioprotective agents, surgery, nutritional support, and symptomatic management. However, their efficacy remains limited. The gut microbiota, a complex microbial community residing in the human digestive tract, is closely linked to human health. Numerous studies have identified gut microbiota dysbiosis in the context of RE. This review illustrates the intricate relationship between RE and the gut microbiota, focusing on the underlying mechanisms of their interaction. It also introduces emerging therapeutic strategies targeting the gut microbiota for RE, including engineered probiotics, washed microbiota transplantation (WMT), and ROS-scavenging nanomaterials, offering novel insights for its diagnosis and treatment.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"640003"},"PeriodicalIF":2.6,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Management of Severe Taxane-Induced Nail Toxicity in a Breast Cancer Patient.","authors":"Natalia Sauer, Marta Kowalczuk, Adrian Arkada, Jacek Calik","doi":"10.2147/CMAR.S606559","DOIUrl":"10.2147/CMAR.S606559","url":null,"abstract":"<p><strong>Introduction: </strong>Taxane-induced nail toxicity (TINT) is a relatively common but often underreported adverse effect of docetaxel-based chemotherapy that may significantly impair quality of life and functional status. Severe cases can require structured supportive care involving multiple clinical disciplines. We present a case of high-grade TINT in a patient with breast cancer successfully managed with a multidisciplinary supportive approach.</p><p><strong>Case presentation: </strong>A 70-year-old woman with HER2-positive breast cancer received neoadjuvant TCH chemotherapy (docetaxel, cyclophosphamide, trastuzumab), followed by surgery and adjuvant trastuzumab emtansine. Nail toxicity developed after the second cycle of docetaxel and progressed to subungual hemorrhages, onycholysis, and marked onychodystrophy associated with pain and functional limitation. The patient underwent podiatric treatment including mechanical nail debridement and topical collagen-based serum therapy. Supportive pharmacologic management, including selective COX-2 inhibitors, was also introduced.</p><p><strong>Results: </strong>Gradual epithelial healing and nail regrowth were observed over a six-month follow-up period. Pain and functional impairment improved, and systemic oncologic therapy was continued without interruption. No recurrence of severe nail complications was noted during subsequent treatment.</p><p><strong>Conclusion: </strong>This case illustrates that severe taxane-induced nail toxicity may be effectively controlled with coordinated multidisciplinary supportive care. Early podiatric intervention combined with pharmacologic symptom management may help maintain treatment continuity and improve patient comfort during taxane-based chemotherapy.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"606559"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Gustave Roussy Immune Score and Survival in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemoimmunotherapy.","authors":"David Sánchez-García, Miguel Borregón-Rivilla, Alejandro Moya-Martínez, María Valero Revert, Beatriz Grau-Mirete, Mariano Martínez-Marín, Elena Navarro-Vicente, Cristina Bernabé Martínez, María Orengo-López, Marta Hernández Sáez, Álvaro Muñoz Abad, Paula Rodríguez-Payá, María Pamies-Ramón, María Guirado-Risueño, Javier-David Benitez-Fuentes, Asia Ferrández-Arias","doi":"10.2147/CMAR.S627848","DOIUrl":"10.2147/CMAR.S627848","url":null,"abstract":"<p><strong>Background: </strong>First-line chemoimmunotherapy has improved outcomes in extensive-stage small-cell lung cancer (ES-SCLC), but survival remains heterogeneous and routine-care prognostic tools are limited.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed consecutive adults with stage IV ES-SCLC treated with platinum-etoposide plus a programmed death-ligand 1 inhibitor at three Spanish hospitals from August 2021 to December 2024. Outcomes included overall survival (OS), progression-free survival (PFS), objective response, and immune-related toxicity. Baseline Gustave Roussy Immune Score (GRIm) was defined as high-risk when at least two of albumin <35 g/L, lactate dehydrogenase above the upper limit of normal, and neutrophil-to-lymphocyte ratio >6 were present. Baseline Cox models included high-risk GRIm, platelet-to-lymphocyte ratio >180, and Eastern Cooperative Oncology Group performance status ≥2; maintenance exposure was assessed in a 3-month OS landmark analysis. Analyses were exploratory.</p><p><strong>Results: </strong>Among 51 patients, mean age was 64.2 years, 72.5% were men, and 82.3% had ECOG performance status 0-1. During follow-up, 43 deaths and 50 PFS events occurred. Objective response rate was 70.6%, median OS was 11.9 months, and median PFS was 5.7 months. Median OS was 14.2 months with low-risk GRIm and 5.4 months with high-risk GRIm. High-risk GRIm was independently associated with worse OS (hazard ratio [HR] 5.59) and PFS (HR 3.50), while PLR >180 was associated with worse OS (HR 2.37). In the 3-month landmark cohort (n=47), maintenance exposure remained associated with longer OS (HR 0.21), although this analysis remained vulnerable to residual selection bias.</p><p><strong>Conclusion: </strong>Baseline GRIm was the most consistent candidate prognostic marker in this real-world ES-SCLC cohort. The study did not assess prediction of immunotherapy benefit, and prospective validation is warranted before treatment decisions are guided by GRIm.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"627848"},"PeriodicalIF":2.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remodeling the Tumor Microenvironment: Mechanistic Insights and Translational Frontiers of TCM-Derived Bioactive Monomers.","authors":"Yunxuan Fei, Jiahui Lu, Zhexian Yu, Chenfei Xu, Meilin Tian, Qianqian Li, Huimin Ye, Ying Lu, Wenli Shen, Qiaohui He, Anjing Wang, Zhezhong Zhang, Haixin Qin, Yaping Yu","doi":"10.2147/CMAR.S613568","DOIUrl":"10.2147/CMAR.S613568","url":null,"abstract":"<p><p>Recent studies have shown that tumor development and therapeutic resistance are closely linked to the tumor microenvironment (TME), a dynamic ecosystem composed of vascular networks, immune and stromal cells, extracellular matrix components, cytokines, and extracellular vesicles. This review summarizes current mechanistic evidence on how bioactive monomers and purified active fractions derived from traditional Chinese medicine (TCM), including polysaccharides, saponins, alkaloids, terpenoids, flavonoids, and polyphenols, regulate TME-associated processes. These compounds have been reported to modulate macrophage polarization, T-cell and natural killer (NK)-cell surveillance, dendritic-cell maturation, myeloid-derived suppressor cell (MDSC) and neutrophil activities, cancer-associated fibroblast (CAF) activation, angiogenic signaling, cytokine networks, exosome-mediated communication, and extracellular matrix remodeling. However, most available evidence remains derived from cell models and animal experiments, and clinical validation is limited. Therefore, TCM-derived bioactive monomers should currently be interpreted as mechanistic probes, lead structures, or candidate adjunctive agents rather than established TME-directed therapies. Future research should prioritize compound standardization, dose-response relationships, pharmacokinetic and toxicological characterization, reproducible model systems, validated TME biomarkers, and controlled clinical trials.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"613568"},"PeriodicalIF":2.6,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13537184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic Combination of Hypericin-Mediated Photodynamic Therapy and HIF-1α siRNA Inhibits Triple-Negative Breast Cancer via Inducing PANoptosis in vitro.","authors":"Xin Wen, Jiangluqi Song, Yirui Yu, Jinhang Hu, Min Cheng","doi":"10.2147/CMAR.S613469","DOIUrl":"10.2147/CMAR.S613469","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with high global morbidity and mortality. Hypericin is a natural photosensitizer that can preferentially accumulate in tumor tissues. Photodynamic therapy (PDT) is an emerging anticancer strategy that eliminates tumor cells through reactive oxygen species (ROS) generation by light-activated photosensitizers in the presence of molecular oxygen. However, PDT-induced oxygen consumption may further aggravate tumor hypoxia. In this study, we evaluated the synergistic antitumor effects of hypericin-mediated PDT combined with siHIF-1α (HYP-siHIF) in TNBC cells.</p><p><strong>Methods: </strong>The MTT assay was performed to evaluate the effects of HYP-PDT alone or in combination with siHIF on TNBC cell viability. Intracellular ROS levels were assessed using the fluorescent probe DCFH-DA. RNA sequencing (RNA-seq) analysis was performed to explore the potential molecular changes induced by HYP-siHIF treatment. Transmission electron microscopy (TEM) and Hoechst staining were used to evaluate cellular morphological alterations, while flow cytometry was performed to assess apoptosis. Western blotting was used to detect the expression levels of proteins associated with cell death pathways.</p><p><strong>Results: </strong>HYP-siHIF significantly inhibited TNBC cell viability, increased intracellular ROS accumulation, and induced morphological and molecular features associated with apoptosis, pyroptosis, and necroptosis. Mechanistically, this study provides evidence that HYP-siHIF activates PANoptosis-related cell death pathways following PDT treatment. For apoptosis, HYP-siHIF increased Bax expression, reduced Bcl-2 expression, and enhanced the cleavage of caspase-9/3/7. For pyroptosis, HYP-siHIF increased NLRP3 expression and promoted the cleavage of GSDMD and GSDME. For necroptosis, HYP-siHIF significantly increased the phosphorylation levels of RIP3 and MLKL.</p><p><strong>Conclusion: </strong>HYP-PDT and siHIF exhibit synergistic antitumor effects, which are associated with the activation of PANoptosis-related cell death pathways. HYP-siHIF may represent a potential therapeutic approach for TNBC that warrants further mechanistic and translational investigation.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"613469"},"PeriodicalIF":2.6,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13537379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Systematic Biopsy Core Number on Clinically Significant Prostate Cancer Detection and Complications in MRI-Ultrasound Fusion Biopsy: A Retrospective Cohort Study.","authors":"Chung Yi Liu, Ying-Hsu Chang, Yu-Hsiang Lin, Po Han Chen, Chun Bi Chang, Li-Jen Wang, Chun-Te Wu, See Tong Pang, Wei Chang Lee, Le Wei Fan, Yun Ren Li, I-Hung Shao","doi":"10.2147/CMAR.S613716","DOIUrl":"10.2147/CMAR.S613716","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the impact of varying systematic biopsy (SB) core numbers on the detection rates of prostate cancer (PCa) and clinically significant PCa (csPCa) in men with magnetic resonance imaging (MRI)-suspicious lesions undergoing MRI-ultrasound fusion biopsy; and to assess biopsy-related complications.</p><p><strong>Methods: </strong>This retrospective, non-randomized cohort study included 356 patients who underwent multi-parametric MRI followed by MRI-ultrasound fusion targeted biopsy (TB) combined with SB for suspected PCa (Prostate Imaging Reporting and Data System score ≥ 3). Patients were divided into two groups based on the number of SB cores received: ≤ 6 SB cores (n = 200) and > 6 SB cores (n = 156). Primary outcomes were overall PCa and csPCa (Gleason Grade Group ≥ 2) detection rates. Secondary outcomes included the added diagnostic value of SB for csPCa, SB upgrading rates, and post-biopsy complications.</p><p><strong>Results: </strong>No significant difference was observed in the overall PCa detection rate between the ≤ 6 cores and > 6 cores groups (58.0% vs 50.0%, P = 0.081) or in the overall csPCa detection rate (42.5% vs 37.2%, P = 0.182). The added diagnostic value of SB for csPCa detection (3.0% vs 3.8%, P = 0.439) and SB upgrading rate (7.0% vs 9.6%, P = 0.241) were comparable between the groups. However, the complication rate was significantly lower in the group receiving ≤ 6 SB cores compared to that receiving the > 6 SB cores (15.5% vs 26.3%, P = 0.009). Subgroup analysis indicated that SB provided significantly higher added value for csPCa detection in older patients (≥ 67 years; 5.3% vs 1.6%, P = 0.049). Multivariable logistic regression demonstrated that receiving >6 SB cores was not significantly associated with increased detection of csPCa.</p><p><strong>Conclusion: </strong>These findings seem support optimizing and potentially reducing the systematic component of combined biopsy. Further prospective studies are warranted to confirm these results and refine personalized biopsy protocols.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"613716"},"PeriodicalIF":2.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Internal Validation of a LASSO-Based Prediction Model for Colorectal Adenoma Recurrence After Polypectomy.","authors":"Kaili Peng, Shuofan Wang, Huaqiang You, Yangkun Dai","doi":"10.2147/CMAR.S620591","DOIUrl":"10.2147/CMAR.S620591","url":null,"abstract":"<p><strong>Background: </strong>Colorectal adenoma recurrence after polypectomy remains an important clinical concern, with current surveillance strategies based primarily on index adenoma characteristics. This study aimed to develop and validate a prediction model integrating clinical and metabolic factors for personalized recurrence risk assessment.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 328 patients with colorectal adenomas confirmed by pathology between January 2018 and December 2021. Variable selection was performed using LASSO-penalized Cox regression with 10-fold cross-validation. Model performance was assessed through bootstrap validation (1000 resamples) with calculation of Harrell's C-index, calibration curves, and decision curve analysis.</p><p><strong>Results: </strong>The final model included age (HR 1.28, 95% CI 1.12-1.47), alcohol consumption history (HR 2.12, 95% CI 1.68-2.67), and bile acid levels (mean 3.14 ± 0.85 μmol/L in the recurrence group vs 2.73 ± 0.78 μmol/L in the non-recurrence group). The model demonstrated good discrimination (bootstrap-corrected C-index 0.878, 95% CI 0.843-0.912) and calibration (slope 0.894, 95% CI 0.851-0.937).</p><p><strong>Conclusion: </strong>The developed prediction model integrating age, alcohol history, and bile acid levels provides a practical tool for stratifying recurrence risk after polypectomy, with potential to guide personalized surveillance strategies. External validation is warranted to confirm these findings.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"620591"},"PeriodicalIF":2.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13535924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathological Spectrum of Thyroidectomy Specimens and Clinicopathological Characteristics of Thyroid Malignancy in Mogadishu, Somalia: A Retrospective Cross-Sectional Study.","authors":"Mohamed Serar Yusuf, Mohamed Mustaf Ahmed, Rahma Mohamed Ali, Abdkerem Abdulahi Abdi","doi":"10.2147/CMAR.S636474","DOIUrl":"10.2147/CMAR.S636474","url":null,"abstract":"<p><strong>Background: </strong>Thyroid cancer incidence is rising globally; however, histopathological data from Somalia are scarce, and no comprehensive characterization of resected thyroid specimens has been reported.</p><p><strong>Methods: </strong>A retrospective review of 438 thyroidectomy specimens reported at a histopathology referral laboratory in Mogadishu, Somalia, between 2022 and 2025 was performed. Each specimen was classified as benign, borderline, or malignant according to the World Health Organization criteria. The associations between malignancy and age and sex were examined using chi-square or Fisher exact tests and unadjusted logistic regression.</p><p><strong>Results: </strong>The cohort was predominantly female (90%), with a median age of 37 years. Benign lesions accounted for 366 specimens, borderline lesions for 8, and malignant lesions for 64, giving an overall malignancy proportion of 14.6%. Nodular and colloid goiters dominated the benign diagnoses, and papillary thyroid carcinoma was the most frequent malignant subtype, accounting for 50 of 64 cases. Malignancy was highest in patients aged 30 years or younger (22.2%), and the variation across age groups was statistically significant. The incidence of malignancy did not differ significantly according to sex. Among malignant tumors, the median size was 3.0 cm, and most were in the early tumor category.</p><p><strong>Conclusion: </strong>Benign goiter dominates thyroid surgical pathology in Mogadishu, while papillary carcinoma leads to a modest malignant burden that is proportionally greatest in younger patients. Strengthening pathology capacity, preoperative cytology, and cancer surveillance is therefore warranted.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"636474"},"PeriodicalIF":2.6,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148856870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peritoneal Metastasis in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion/T790M with STRN::ALK Fusion and EGFR Kinase Domain Duplication: Two Case Reports and a Narrative Literature Summary.","authors":"Hao Zhang, Jun Han, Feng Rong","doi":"10.2147/CMAR.S612868","DOIUrl":"10.2147/CMAR.S612868","url":null,"abstract":"<p><p>Peritoneal metastasis from lung adenocarcinoma is rare and generally associated with poor prognosis. Here, we report two cases of advanced NSCLC with multiple metastases in which the patients developed rare peritoneal metastases during disease progression. Next-generation sequencing (NGS) revealed rare genomic alterations: one patient harbored concurrent EGFR exon 19 deletion and T790M mutation, accompanied by EGFR amplification, TP53 mutation, and STRN::ALK fusion, while the other exhibited EGFR kinase domain duplication and TP53 mutation. Both patients underwent multiple lines of systemic therapy, including targeted treatment guided by NGS results, and achieved survival exceeding six months following the diagnosis of peritoneal metastasis, with ongoing treatment at last follow-up. These observations suggest that more precise molecularly guided targeted therapy may play a crucial role in the clinical management of peritoneal metastasis.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"612868"},"PeriodicalIF":2.6,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13525806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer Chemoresistance: Insights into the Regulatory Role of lncRNAs.","authors":"Maodan Hou, Jiangyan Chen, Peng Yi, Hao Liu, Xin Li, Guihua Wang","doi":"10.2147/CMAR.S623665","DOIUrl":"10.2147/CMAR.S623665","url":null,"abstract":"<p><p>Lung cancer remains the leading cause of cancer-related mortality worldwide, with chemoresistance being a major challenge in its treatment. Long non-coding RNAs (lncRNAs), a class of transcripts longer than 200 nucleotides without protein-coding potential, have emerged as critical regulators in tumour progression and drug resistance. This review systematically summarizes the multifaceted mechanisms through which lncRNAs influence chemoresistance across major lung cancer subtypes, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including regulation of cell proliferation, cell cycle progression, migration, invasion, apoptosis, pyroptosis, necroptosis, and autophagy. Some key lncRNAs function as competing endogenous RNAs (ceRNAs) to sponge microRNAs, modulate chromatin architecture, or alter key signalling pathways (eg, PI3K/Akt, Wnt/β-catenin, and JAK2/STAT3), ultimately promoting survival and chemoresistance of lung cancer cells under chemotherapeutic stress. Clarification of these mechanisms provides novel insights into the development of early diagnostic markers and therapeutic targets. Future research should focus on elucidating specific lncRNA interactions, developing lncRNA-based therapeutics, and exploring their roles in tumour microenvironments and drug-resistant subpopulations to overcome chemoresistance.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"623665"},"PeriodicalIF":2.6,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13510243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}